Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-negative CD19-positive B-cell precursor ALL
Findings from the SGNTUC-019 study
Findings from a translational analysis of the FOENIX study and a comprehensive analysis of primary data from a multi-institutional patient cohort with FGFR-altered cholangiocarcinoma
Findings from the TROPION-Lung05 study
Evidence for efficacy is based on the results from the BREAKWATER study
Change concerns the first-line treatment of patients with endometrial cancer
Findings from the KATHERINE study
Findings from a substudy 02C of the KEYMAKER-U02 trial
Findings from the RedirecTT-1 study
Evidence for efficacy is based on the results from the ADRIATIC study
It is intended for the treatment of patients with advanced clear cell renal cell carcinoma and von Hippel-Lindau disease-associated tumours
Findings from the EMERALD-1 and LEAP-012 studies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
